Cardiac resynchronization therapy: are modern myths preventing appropriate use?

[1]  Michael E. Miller,et al.  ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .

[2]  B. Wilkoff,et al.  Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. , 2009, Journal of the American College of Cardiology.

[3]  N. Freemantle,et al.  The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial , 2008, European heart journal.

[4]  Nick Freemantle,et al.  Long‐term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE‐HF trial , 2009, European journal of heart failure.

[5]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[6]  J. Cleland,et al.  Cardiac resynchronization therapy: dyssynchrony imaging from a heart failure perspective , 2008, Current opinion in cardiology.

[7]  J. Cleland,et al.  Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK‐1827452 , 2008, European journal of heart failure.

[8]  N. Freemantle,et al.  Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. , 2008, Journal of the American College of Cardiology.

[9]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[10]  J. Cleland,et al.  The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction , 2008, European journal of heart failure.

[11]  J. Cleland,et al.  The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure , 2007, European journal of heart failure.

[12]  J. Daubert,et al.  Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study , 2007, Heart.

[13]  Nick Freemantle,et al.  Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. , 2007, European heart journal.

[14]  J. Daubert,et al.  Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. , 2006, European heart journal.

[15]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[16]  J. Cleland,et al.  Cardiac resynchronization therapy or atrio-biventricular pacing—what should it be called? , 2007, Nature Clinical Practice Cardiovascular Medicine.

[17]  J. Daubert,et al.  Predicting the long-term effects of cardiac resynchronisation therapy from baseline variables and the early response. A report from CARE-HF (Cardiac Resynchronisation in Heart Failure) , 2006 .

[18]  Nick Freemantle,et al.  Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. , 2006, European heart journal.

[19]  N. Freemantle,et al.  Clinical trials update from the American College of Cardiology meeting: CARE‐HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS‐HF, VERITAS, CANPAP, PEECH and PREMIER , 2005, European journal of heart failure.

[20]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[21]  J. Daubert,et al.  Baseline characteristics of patients recruited into the CARE‐HF study , 2005, European journal of heart failure.

[22]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[23]  J. Cleland.  Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. , 2002, Progress in cardiovascular diseases.

[24]  N Freemantle,et al.  The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points , 2001, European journal of heart failure.

[25]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[26]  J. Daubert,et al.  Permanent Left Ventricular Pacing With Transvenous Leads Inserted Into The Coronary Veins , 1998, Pacing and clinical electrophysiology : PACE.

[27]  R. Peters,et al.  Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. , 1995, British heart journal.

[28]  A. Auricchio,et al.  LETTERS TO THE EDITOR , 1995 .

[29]  M. Mower,et al.  Multiple chambered pacing for treatment of congestive heart failure. , 1995, Pacing and clinical electrophysiology : PACE.

[30]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.